[1] Dapito DH,Mencin A,Gwak GY,et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.Cancer Cell,2012,21:504-516. [2] 董永绥. 肠道菌群失调、内毒素与小儿胃肠功能障碍.中国实用儿科杂志,2001,16(1):5-10. [3] Vanderpool C,Yan F,Polk DB. Mechanisms of probioticaction:hnplications for therapeutic applications ininflammatory bowel diseases. Inflamm Bowel Dis,2008,14(11):1585-1596. [4] 尹军霞,林德荣.肠道菌群与疾病.生物学通报,2004,39(3):26. [5] Wigg AJ,Roberts-Thomson IC,Dymock RB,et a1. The role ofsmall intestinal bacterial overgrowth,intestinal permeatility,endotox-aemia,and tumour necrosis factor-a in the pathogensis, Defilippi CL. Deficippi CA,of non-alcoholic steatophepatitis. Gut,2001,48:206-211. [6] 王为,周国华,冷明芳,等. 酒精性肝病患者小肠细菌过度生长情况研究.中华临床医师杂志,2009,3(11):86-88. [7] 张爱军,战淑慧,许琳,等. 肝硬化患者小肠细菌过度生长与肝功能及自发性腹膜炎的关系. 肝脏,2009,14(5):389-390. [8] 刘扬,李媛,许琳,等. 小肠细菌过度生长与小肠肿瘤的关系及其临床意义. 世界华人消化杂志,2013,31:3435-3439. [9] 王为,刘峰,徐爱蕾,等. 三种消化道恶性肿瘤小肠细菌过度生长情况的研究. 医学综述,2011,17 (6):946-947. [10] Bustillo I,Larson H,Saif MW. Small intestine bacterial overgrowth:an under-diagnosed cause of diarrhea in patients with pancreatic cancer. J Pancreas,2009,10:576-578. [11] Sadik R,Abrabamason H,Bjornsson E,et a1. Etiology of portal hypertension may influence gastrointestinal transit. Scand J Gastroenterol,2003,38(10):1039-1044. [12] Ramachandran A,Prabhu R,Thomas S,et a1. Intestinal mucosal alterations in experimental cirrhosis in the rat:role of oxygen flee radicals.Hepatology,2002,35(3):622-629. [13] 楼俪泓,靖大道. 肝硬化与肠道屏障功能障碍.胃肠病学,2005,10(4):243-245. [14] 贾辅忠.肝病与肠道微生态环境. 中国实用内科学杂志,2006,26(13):971-974. [15] Schroder J,Wardelmann E,Winkler W,et al. Glutamine dipeptide-supplemented parenteral nutrition reverses gut atrophy, disaccharidase enzyme activity,and absorption in rats. J Parenter Enteral Nutr,1995,19(6):502-506. [16] 石刚,陈嘉勇,徐鹏远. 肠道粘膜屏障的损伤与保护.肠外与肠内营养,2004,11(1):61-63. [17] Lombardo L,Foti M,Ruggia O,et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol,2010,8:504-508. [18] Kasravi FB,Wang L,Wang XD,et a1. Bacterial translocationin acute liver injury induced by D-galactosamine. Hepatology, 1996,23(1):97-103. [19] 王锦辉,陈旻湖,孙光裕,等.肝硬化患者小肠细菌过度生长与内毒素血症.中华内科杂志,2002,41(7):459-461. [20] 刘伟,蒋义斌,钟良,等.慢性肝病小肠细菌过度生长与内毒素血症.中华消化杂志,2005,25(7):398-400. [21] 田峰,饶芳,梁少红,等. 微生态制剂联合莫沙必利治疗肝硬化患者内毒素血症的临床研究.中国医药指南,2010,8(24):98-100. [22] Hatano E,Tannka A,Iwata S,et a1. Induction of endotoxin tolerance in transgenic mouse liver expressing. Hepatology,1996, 23:669. [23] 贾淑云,韩德五,马学惠,等. 肝功能衰竭发病机制的研究-肠源性内毒素血症假说. 中华肝脏病杂志,1995,3:80-82. [24] Shimazu R, Akashi S,Ogata H,et a1. MD-2,a molecule that conferslipopolysaccharide responsiveness on Toll-like receptor. J Exp Med,1999,189(11):1777-1782. [25] Strain S,Fesik SW,Armitage IM. Characterization of lipopolysaccharide from a heptoseless mutant of Escherichia coli by carbon 13 nuclear magnetic resonance. J Biol Chem,1983,258(5):2906-2910. [26] Paik YH,Schwabe RF, Bataller R,et al. Toll-like receptor 4 mediatesinflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology,2003,37(5):1043-1055. [27] Takeda K,Kaisho T,Akira S. Toll-like receptors. Annu Rev Immunol,2003,21:335-376. [28] 陈圻,邓存良. TLR4在肝脏损伤中的作用研究进展.医学综述,2008,14(19):2897-2899. [29] Huang B,Zhao J,Li H,et a1. Toll-like receptors on tumor cells facilitateevasion of immune surveillance. Cancer Res,2005,65(12):5009-5014. [30] Schmausser B,Andrulis M,Endrich S,et a1. Toll-like receptorsTLR4,TLR5 and TLR9 on gastric carcinoma cells:an implication for interaction with Helicobacter pylori. Int J Med Microbiol,2005,295(3):179-185. [31] Wang L,Liu Q,Sun Q,et a1. TLR4 signaling in cancer cellspromotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochem Biophys Res Commun,2008,366(3):852-856. [32] 陈超,张怀强,相磊,等.TLR4在膀胱尿路上皮癌中的表达及意义.山东大学学报:医学版,2009,47(10):80-82. [33] Gonzalez Reyes S, Marin L,Gonzalez L,et a1. Study of TLR3,TLR4 and TLR9 in breast carcinomas and their association withmetastasis.BMC Cancer,2010,10(1):665-667. [34] Luedde T,Schwabe RF. NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol,2011,8:108-118. [35] P-lsson-McDermott EM,O’Neill LA. Signal transduction by the lipopolysaccharide receptor,Toll-like receptor-4.Immunology, 2004,113(2):153-162. [36] Akira S,Takeda K. Toll-like receptor signaling. Nat Rev Immunol,2004,4(7):499-511. [37] Barton GM,Medzhitov R. Toll-like receptor signaling pathways. Science,2003,300(5625):1524-1525. [38] Yu LX,Yan HX, Liu Q,et al. Endotoxinaccumulation prevents carcinogen-induced apoptosis and promotes livertumorigenesis in rodents. Hepatology,2010,52:1322-1333. [39] Wang LL,Zhu R,Huang ZQ,et al. Lipopolysaccharide-induced Toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci,2013,58(8):2223-2236. |